Videos

Experts on multiple myeloma address the intricacies of adverse event management practices, focusing on taste changes and associated weight loss.

Panelists discuss how specific biomarkers, such as GPRC5D expression levels, and clinical features, influence their decision to initiate GPRC5D bispecific therapies in multiple myeloma patients.

The panel discusses how they approach treatment selection and sequencing for patients with relapsed/refractory multiple myeloma.

Samantha Shenoy, NP, MSN, presents the case of a patient with multiple myeloma and the panel discusses adverse event management practices.

Shaji Kumar, MD, presents the case of a 70-year-old patient with relapsed/refractory multiple myeloma who received CAR T-cell therapy.

Panelists discuss how collaborative care settings for multiple myeloma patients often lead to improved outcomes compared to non-collaborative approaches, citing factors such as access to specialized expertise, coordinated treatment plans, and comprehensive patient support.

The Foundation for Women’s Cancer provides multicultural resources for patients with gynecologic cancers to help address gaps in care.

Ginger J. Gardner, MD, FACOG, addresses the growing uterine cancer cases among patients in the United States and the need for greater genetic testing.

Panelists discuss the immune profiles of responders vs non-responders to pelabresib in myeloproliferative neoplasms (MPNs).

Ginger J. Gardner, MD, FACOG, discussed the state of gynecologic cancers and her role in empowering research, education, and awareness surrounding them.

James Ninia, MD, discussed a phase 2/3 trial seeking to answer whether complete consolidation offers more benefit than incomplete consolidation in SCLC.

Overall survival benefit was significant with complete vs incomplete consolidation therapy, but lost significance when stratified by disease burden.

James Ninia, MD, discussed treatment options for patients with extensive-stage small cell lung cancer undergoing metastasis-directed radiotherapy.

Panelists discuss how the MARIPOSA study shows more patients in the amivantamab-lazertinib arm continued treatment compared to osimertinib, and many who progressed initiated subsequent therapy, primarily with carboplatin-pemetrexed.

Panelists discuss the frequency, timing, and symptoms of infusion-related reactions with amivantamab plus lazertinib, how these drugs compare with other treatments such as datopotamab deruxtecan (DXd) or patritumab DXd (HER3-DXd), and the management strategies and prophylactic measures used, especially for patients with EGFR exon 19 or L858R advanced/metastatic non–small cell lung cancer who have experienced progression on prior therapies.

Whole or accelerated partial breast ultra-hypofractionated radiation in older patients with early breast cancer may reduce recurrence with low toxicity.

Ultra-hypofractionated radiation in those 65 years or older with early breast cancer yielded no ipsilateral recurrence after a 10-month follow-up.

The unclear role of hypofractionated radiation in older patients with early breast cancer in prior trials incentivized research for this group.

Panelists discuss how streamlining the referral process for multiple myeloma patients can significantly reduce treatment initiation.

Panelists discuss how effective collaboration, care coordination, and communication between academic and community physicians are crucial for ensuring seamless transitions and high-quality care for patients with multiple myeloma.

The panel provides an overview of REMS programs for bispecific therapies in multiple myeloma and discusses how institutions can educate healthcare professionals outside of oncology.

Experts on multiple myeloma discuss prophylactic supportive measures to prevent CRS and ICANS in patients who receive GPRC5D therapy.

Noopur Raje, MD, discusses the role of T-cell affinity in bispecific therapy for patients with relapsed/refractory multiple myeloma and how it impacts treatment practices.

The panel discusses the benefits of having multiple BCMA-targeting bispecifics available for patients with relapsed/refractory multiple myeloma.

Medical experts describe the decision-making process between choosing an IO-IO vs an IO-TKI regimen for first-line treatment, considering factors such as safety profile and response in both community and academic settings.

Medical experts will discuss the updated NCCN guidelines favoring ipilimumab + plus nivolumab for patients with favorable risk, including the data supporting this change and its the potential impact on the disease landscape.

The discussion shares key takeaways and practical insights for optimizing the referral and treatment process for CAR T-cell and bispecific therapies.

The discussion focuses on protocols for monitoring long-term complications from CAR T-cell and bispecific therapies, improving patient reintegration into community care posttreatment, and enhancing communication between academic and community oncologists.

Panelists discuss how patient selection for GPRC5D-targeted therapies in the relapsed/refractory setting is guided by factors such as prior treatment history, including the number and types of previous therapies, with special consideration given to patients who have exhausted other options or shown resistance to earlier lines of treatment.

Panelists discuss how certain patient subgroups, such as those with high-risk cytogenetics or extramedullary disease, may experience different outcomes with GPRC5D bispecific therapies, though more data is needed to draw definitive conclusions about subgroup-specific responses.